Video Experimental Relacionado
Updated: Jan 25, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.2K
Mavacamten en la miocardiopatía hipertrófica obstructiva: la primera experiencia australiana
Antony Chun Fai So1, Kathryn A Davison2, Teresa Hecker3
1Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, SA, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia; Cardiac Imaging Research, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
Heart, lung & circulation
|January 23, 2026
Resumen
El mavacamten redujo significativamente los síntomas de la miocardiopatía hipertrófica obstructiva (MHO) y los gradientes del tracto de salida del ventrículo izquierdo (TSVI) en pacientes australianos. El inhibidor de la miosina cardíaca demostró un perfil de seguridad tolerable durante 24 semanas.
Área de la Ciencia:
- Cardiología; Farmacología; Medicina Clínica
Sus antecedentes:
- El mavacamten, un nuevo inhibidor de la miosina cardíaca, está aprobado en Australia para la miocardiopatía hipertrófica obstructiva (MHO).; Estudios internacionales confirman la eficacia del mavacamten, pero faltaban datos australianos del mundo real.; Este estudio aborda la necesidad de datos australianos del mundo real sobre el impacto y la seguridad del mavacamten.
Objetivo del estudio:
- Evaluar la eficacia del mavacamten en el mundo real en pacientes australianos con MHO sintomática.; Evaluar la seguridad y tolerabilidad del mavacamten en esta cohorte.; Analizar los cambios en los parámetros hemodinámicos y funcionales durante 24 semanas.
Principales métodos:
- Un estudio observacional unicéntrico de 23 pacientes con MHO sintomática tratados con mavacamten.; Evaluación de parámetros ecocardiográficos basales y a las 24 semanas (gradientes del TSVI, FEVI, función longitudinal global del VI) y clase NYHA.; Monitorización de eventos adversos emergentes del tratamiento y adherencia del paciente.
Principales resultados:
- El mavacamten redujo significativamente los gradientes del TSVI en reposo (de 56 a 16 mmHg) y de Valsalva (de 92 a 37 mmHg) (p<0,001).; El 70 % de los pacientes mostraron al menos una mejora en la clase NYHA, con alta adherencia (99 %).; Se observó un perfil de seguridad tolerable, con un 13 % de interrupción del tratamiento debido a eventos adversos.
Conclusiones:
- El mavacamten proporciona beneficios clínicos y ecocardiográficos significativos en pacientes australianos con MHO.; El fármaco demuestra un perfil de seguridad tolerable dentro de los primeros 6 meses de uso.; Este estudio ofrece valiosos datos australianos del mundo real sobre la terapia con mavacamten.
Videos de Conceptos Relacionados
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
451
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
451
01:30Cardiomyopathy II: Dilated Cardiomyopathy
509
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
509
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
496
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
496
01:29Cardiomyopathy V: Interprofessional Care
370
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
370
01:25Cardiomyopathy I: Introduction and Classification
545
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
545
01:29Cardiomyopathy VI: Nursing Management
332
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
332